#USA #Atlanta #Field Medical #PFA System #Field PULSE

Field Medical's Breakthrough in Cardiac Ablation: The Field PULSE Trial Results

Field Medical, Inc. has recently released the 12-month outcomes from its pioneering Field PULSE trial, showcasing a groundbreaking advancement in the treatment of complex arrhythmias. The findings, made public in the JACC Clinical Electrophysiology, reveal a stunning durability rate of 94.2% per-vein pulmonary vein isolation (PVI) using their high-voltage focal pulsed field ablation (PFA) system. This trial marks a significant step in the quest for efficient and safe solutions in cardiac care.

Overview of the Field PULSE Trial

Conducted as a first-in-human study, the Field PULSE trial aimed to assess the efficacy of Field Medical's innovative FieldForce™ PFA system specifically designed to tackle the challenges faced during ablation procedures. The trial was presented simultaneously at the HRX Live 2026, highlighting its importance and the promising outcomes for patient care.

According to Dr. Vivek Reddy, a co-principal investigator of the study, the trial demonstrates the feasibility of achieving instantaneous focal PFA. This process aims to address the challenges presented by prolonged catheter stability – a common hurdle in the field. The results indicate that a less than 200 milliseconds delivery time for treatments minimizes the need for extended catheter stability while ensuring the flexibility of point-by-point ablation.

Key Findings from the Trial

The results of the Field PULSE trial were revelatory:

• - Procedure Efficiency: The field PFA achieved a median ablation time of just 13 minutes, with an impressive record of 7.7 minutes for the fastest cases.
• - PVI Durability: The use of an optimized waveform has led to a remarkable 94.2% durability rate for PVI, showcasing notable improvement through advancements in waveform technology.
• - Flexible Approaches: Nearly half of the patients (49%) benefited from non-pulmonary vein ablation, opening doors for additional atrial targets.
• - Safety Profile: There were no observed primary safety events during the trial, reinforcing the safety of the procedure.
• - Atrial Arrhythmia Freedom: The optimized waveform has also led to an 80% success rate in preventing atrial arrhythmias after a year.

Implications for Cardiac Treatments

These outcomes not only affirm the effectiveness of the FieldForce™ PFA system but also pave the way for more refined treatment options for patients suffering from complex arrhythmias. As Dr. Mark A. Turco, President and CEO of Field Medical, noted, the findings underline that a single high-voltage focal PFA architecture can accommodate both ventricle and atrium patients efficiently. The swift pace and precision of this technology present a versatile tool for addressing varied cardiac substrate challenges.

Future Directions

The significance of the Field PULSE findings is underscored by the growing body of evidence surrounding Field Medical's work in the arrhythmia treatment domain. Previous studies, including the six-month results from their VCAS trial, published in Circulation, have provided foundational clinical data that enhances the credibility of their technology.

As research and development in cardiac medical technology continues to evolve, so too does the potential for improved patient outcomes through innovative strategies such as those explored in the Field PULSE trial.

Field Medical remains committed to incorporating these advancements into clinical practice, aspiring to redefine the standards for ablation techniques in the healthcare landscape. For more information on their emerging technologies and insights, visit Field Medical’s official website.